ArticleJournal of multidisciplinary healthcare2025
The Impact of Clinical Pharmacist Consultation on the Treatment of Multi-Drug Resistant Organisms (MDRO) Infections: A Retrospective Observational Study.
Article in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A practical nomogram for predicting multidrug-resistant organism infection in a tertiary county-level hospital to guide antimicrobial therapy.New microbes and new infections · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Multidrug-resistant organisms (MDROs) infections are associated with high mortality in hospitalized patients. Clinical pharmacists play a crucial role in optimizing anti-infection treatment strategies. This study aimed to evaluate the impact of clinical pharmacist consultation on the treatment of inpatients with MDRO infections. Methods: Patients infected with MDROs who received clinical pharmacist consultation between June 2020 and June 2023 were enrolled. The adoption rate and effectiveness rate of consultation were calculated. Univariate and multivariate logistic regression analyses were conducted to identify factors influencing the effectiveness rate of consultation. Cox regression analysis was employed to estimate the 30-day survival rate post-consultation for patients infected with MDROs, comparing those who adopting pharmacists' suggestions with those who did not. Results: A total of 620 patients were included. More patients were from the surgical system, especially neurosurgery. The top 3 infection sites were respiratory tract, urinary tract and blood, with prevalent MDROs including Carbapenem-resistant Klebsiella pneumoniae (CRKP), Carbapenem-resistant Acinetobacter baumannii (CRAB), and Carbapenem-resistant Pseudomonas aeruginosa (CRPA). Following the implementation of consultation recommendations, patients exhibited significant reductions in temperatures, inflammatory markers, and Sequential Organ Failure Assessment (SOFA) scores. The adoption and effectiveness rate of consultation were 89.67% and 58.71%, respectively. Multivariate analysis showed that there were significant association of liver dysfunction (adjusted OR = 0.331, 95% CI: 0.217-0.504), severity of infection (adjusted OR = 0.292, 95% CI: 0.151-0.562) and adopting pharmacists' suggestions (adjusted OR = 1.987, 95% CI: 1.126-3.507) with the effectiveness rate of consultation. Cox regression analysis revealed a significant difference in the 30-day survival rate between MDRO patients who received pharmacist recommendations and those who did not (HR = 0.422, 95% CI: 0.185-0.963, P = 0.04). Conclusion: Our research indicated that the involvement of clinical pharmacists could be advantageous for patients afflicted with MDRO infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.